Video is part of ms

Dystonia in a female fragile X premutation carrier: a case report

Victoria Ros-Castelló MD1, Anna Latorre MD, PhD2, Juan Álvarez-Linera MD3, Juan C Martinez-Castrillo MD, PhD1, Kailash P Bhatia FRCP, MD2, Isabel Pareés MD, PhD1

1Neurology Department, Hospital Ramón y Cajal, IRYCIS, Madrid, Spain.
2Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, United Kingdom.
3Radiology Department, Hospital Ruber Internacional, Madrid, Spain.

Corresponding author: Victoria Ros Castelló

Address: Ctra. De Colmenar Viejo, km. 9,100, 28034 Madrid, Spain
Telephone: 0034687481404
Email address: victoriaroscastello@gmail.com

Short running title:
Dystonia in a female FMR1 premutation carrier

Key words: dystonia, fragile X syndrome, FMR1 premutation, FXTAS

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/mdc3.13234

This article is protected by copyright. All rights reserved.
Fragile X-associated tremor ataxia syndrome (FXTAS) is the most common neurological manifestation described in carriers of a premutation expansion (55–200 CGG repeats) of the fragile X mental retardation 1 (FMR1) gene\(^1\). FXTAS affects mainly men, partially because of a protective effect of the second X chromosome in females\(^1\). Female carriers often develop FMR1-related primary ovarian insufficiency but movement disorder phenotypes other than FXTAS have rarely been described\(^1\). Here, we report a female carrying the FMR1 premutation who presented in our clinic with cervical dystonia as the main symptom.

**CASE REPORT**

This 59-year-old woman was referred to our movement disorders clinic because of progressive head tremor since age 58. She had a son aged 29 years old with fragile-X syndrome and she had been found to be a carrier of the premutation expansion of the FMR1 gene in the family screening. She was not on any medication. The neurological examination showed mild saccadic intrusions in slow pursuit movements and a “no-no” head tremor with right torticollis. Gait was normal and there were no other cerebellar signs including intention tremor (Video 1). She did not report any sensory trick for her dystonia. Laboratory tests, including ceruloplasmin, copper, ferritin and thyroid function, were normal. Genetic testing revealed 90 CGG repeats in the FMR1 gene. Brain MRI showed no abnormalities in cerebellum, middle cerebellar peduncles (MCP) or corpus callosum in FLAIR, diffusion tensor imaging or fractional anisotropy (Figure 1). No specific treatment was started, as she did not report a significant impact of her symptoms in her daily life.

**DISCUSSION**

We herein report a female FMR1 premutation carrier who presented with cervical dystonia as the main clinical phenotype in whom other secondary causes of dystonia were excluded.
Since the initial description, an increasing number of women with FXTAS have been identified, but there are very few reports of female FMR1 premutation carriers presenting with dystonia. A small case series has suggested that dystonia and bruxism present more commonly in female FMR1 premutation carriers than in the general population and a prevalence of 35% (8 out of 23 female carriers) for dystonia compared to 0.73% (p < 0.01) has also been reported. Of those with dystonia, only four presented with cervical involvement. A case of oromandibular dystonia in a patient carrying the FMR1 premutation has also been reported and only one female patient with FXTAS diagnosis who presented with cervical and laryngeal dystonia has been published to date.

Our patient did not meet criteria for FXTAS. Therefore, our report contributes to the previous literature emphasizing that dystonia should be included in the spectrum of clinical manifestations in FMR1 premutation carriers. That is of interest as dystonia is not included in the diagnostic criteria of FXTAS and could potentially be another etiology of the tremor seen in FXTAS.

Premutation carriers have slightly reduced FMR1 protein levels with significant elevation of FMR1 messenger RNA (mRNA) and a potential toxic effect in brain white matter and motor fiber tracts has been proposed. Pathophysiologic findings in patients with FXTAS include marked dropout of Purkinje cells and white matter disease throughout the cerebellum, including the MCP. Typical neuroimaging findings in patients with FXTAS include brain and cerebellar atrophy and white matter tracts changes with involvement of the MCP known as the MCP sign. Radiological abnormalities in thalamus, basal ganglia and the splenium of the corpus callosum have also been reported. However, radiologic findings are milder in female premutation carriers as compared with males and white matter hyperintensities in the splenium and genu of corpus callosum are more frequent than the MCP sign.

Recent studies have suggested that alterations in activity, connectivity and structure of the cerebellum may play a role in the development of dystonia. There is evidence supporting that cerebellar atrophy, cerebellar degenerative disease, cerebellar lesions and histopathological alterations such as Purkinje cell loss or dentate nucleus cell loss may be associated with dystonia. One could argue that abnormalities in the cerebellum and its connections with the basal ganglia and motor cortex may be involved in the development
of dystonia in patients with the FMR1 premutation. Our patient did not display abnormalities in the neuroimaging studies, which is in concordance with the previous mentioned low rate of brain MRI abnormalities in females. However, it could be suggested that dystonia is a manifestation secondary to a cerebellar dysfunction occurring without neuroimaging evidence of the disease or even before neuroimaging abnormalities occur. Further follow-up is warranted to assess clinical and neuroimaging disease progression in those patients.

In conclusion, our case supports the previous suggestion that dystonia can be part of the clinical spectrum of females carrying a premutation expansion in the FMR1 gene and that FMR1 premutation-sized repeat expansions should be added to the differential diagnosis of craniocervical dystonia in females. However, larger studies are needed to confirm this clinical observation.

Author Roles:


1. VRC: 1A, 1B, 1C, 3A
2. AL: 1C, 3A, 3B
3. JAL: 1C, 3B
4. JCMC: 3B
5. KB: 1A, 3B
6. IP: 1A, 1B, 3A, 3B

Disclosures

Funding Sources and Conflict of Interest: The authors declare that there are no funding sources or conflicts of interest relevant to this work.

Financial Disclosures for the previous 12 months:
VRC has received honoraria as an speaker from Zambon.

JCMC has received honoraria as an speaker from AbbVie, Allergan, Bial, Krka, Merz, Ipsen, Italfarmaco, Medtronic, TEVA, and Zambon; travel grants from AbbVie, Allergan, Bial, Italfarmaco, TEVA, Merz, Krka and Zambón; research grants from AbbVie, Allergan, Merz, Italfarmaco, and Zambon; and participated in advisory boards of AbbVie, Allergan, Bial, Merz, Italfarmaco, Lundbeck, Orion, UCB, and Zambon.

KPB has received grant support from Horizon 2020 EU grant 634821 and honoraria/financial support to speak/attend meetings from GSK, Boehringer-Ingelheim, Ipsen, Merz, Sun Pharma, Allergan, Teva, Lundbeck and Orion pharmaceutical companies. KPB receives royalties from Oxford University press and a stipend for MDCP editorship. This research study was supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre and the Edmond J. Safra Philanthropic Foundation.

IP has received travel expenses to attend scientific meetings from Neuroaxpharm and International Parkinsonism and Movement Disorder Society and honoraria for speaking at meetings from Allergan, and International Parkinsonism and Movement Disorders Society.

**Ethical Compliance Statement**

We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. The authors confirm that the approval of an institutional review board was not required for this work. Oral informed consent was obtained from the patient.

**References**


Legend

Figure 1. Brain MRI showing no abnormalities in cerebellum and middle cerebellar peduncles in FLAIR (A), corpus callosum in sagittal FLAIR (B)
and diffusion tensor imaging with tractography (C) or fractional anisotropy (D).

**Video**

**Video 1.** Segment 1: “No-no” head tremor with right torticollis. Segment 2. Finger to nose test with no cerebellar signs. Segment 3. Normal tandem walking test. Segment 4. Null point: tremor is alleviated when head is turned completely to the right.